- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on FGFR3 Gene Mutation in New Zealand
Total 253 results
-
TransThera Sciences (Nanjing), Inc.CompletedCholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Fusion | FGFR1 Alteration | FGFR3 AlterationUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene AmplificationUnited States, Canada
-
Relay Therapeutics, Inc.Active, not recruitingCholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, AdultUnited States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 MutationFrance, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
-
QED Therapeutics, Inc.Helsinn Healthcare SATerminatedFGFR2 Gene Mutation | Advanced CholangiocarcinomaKorea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
-
QED Therapeutics, Inc.Helsinn Healthcare SATerminatedFGFR2 Gene Mutation | Advanced CholangiocarcinomaUnited States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
-
Memorial Sloan Kettering Cancer CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditionsUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
-
Columbia UniversityRecruitingCancer | Insulin Resistance | MTOR Gene Mutation | PI3K Gene Mutation | AKT Gene MutationUnited States
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
Nested Therapeutics, IncRecruitingGlioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene MutationAustralia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHereditary Breast and Ovarian Cancer Syndrome | Premenopausal | Deleterious BARD1 Gene Mutation | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Deleterious BRIP1 Gene Mutation | Deleterious EPCAM Gene Mutation | Deleterious MLH1 Gene Mutation | Deleterious MSH2 Gene Mutation | Deleterious... and other conditionsUnited States
-
Taiho Oncology, Inc.Active, not recruitingAdvanced Cholangiocarcinoma | FGFR2 Gene RearrangementsUnited States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; Applied Health Research Centre; Takeda Canada, Inc.; Programs...RecruitingCancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene MutationCanada
-
Incyte CorporationTerminatedAdvanced or Metastatic Solid Tumors | FGFR Mutations | FGFR TranslocationsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
Dana-Farber Cancer InstituteJohns Hopkins University; GlaxoSmithKline; Translational Breast Cancer Research...RecruitingBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer | Deleterious PALB2 Gene Mutation | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene MutationUnited States
-
NYU Langone HealthRecruitingMLH1 Gene Mutation | RAD51C Gene Mutation | BRIP1 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | BRCA-Mutated Ovarian Carcinoma | MSH2 A636P | EPCAMUnited States
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedBreast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV | Solid Carcinoma | HER2-negative Breast Cancer | MEK1 Gene Mutation | MEK2 Gene MutationUnited States
-
PfizerMedivation, Inc.; Myriad Genetic Laboratories, Inc.TerminatedBreast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene MutationUnited States, Spain, United Kingdom, Germany, France
-
Memorial Sloan Kettering Cancer CenterRecruitingBladder Cancer | Recurrent Bladder Cancer | FGFR3 Gene MutationUnited States
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.Active, not recruitingBreast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene MutationItaly, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
-
PfizerMedivation, Inc.CompletedBreast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene MutationKorea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
-
Tyra Biosciences, IncRecruitingSolid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditionsAustralia, United States, France, Spain
-
Calithera Biosciences, IncTerminatedNon-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene MutationUnited States
-
Kidney Cancer Research BureauRecruitingMetastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene AmplificationUnited States
-
HutchmedRecruitingIsocitrate Dehydrogenase Gene MutationSpain, United States
-
National Cancer Institute (NCI)Glaxosmithkline Biologicals S.A.TerminatedRenal Failure | Solid Neoplasm | BRAF Gene Mutation | Hepatic ComplicationUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingGlioma | Oligoastrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | 1p/19q Co-deletionUnited States
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
-
Calithera Biosciences, IncTerminatedNon-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 MutationUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditionsUnited States
-
Recursion Pharmaceuticals Inc.RecruitingSolid Tumor | APC Gene Mutation | AXIN1 Gene MutationUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingStudy of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerThyroid Cancer | Anaplastic Thyroid Cancer | BRAF Gene Mutation | BRAF Mutation-Related TumorsUnited States
-
Roswell Park Cancer InstituteAstraZenecaActive, not recruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous AdenocarcinomaUnited States
-
Sebastian BauerHannover Medical School; University Hospital Tuebingen; Universitätsmedizin Mannheim and other collaboratorsUnknownGIST, Malignant | KIT Gene Mutation | KIT Exon 13 MutationGermany
-
OnKure, Inc.Active, not recruitingMelanoma | NRAS Gene Mutation | RAS MutationUnited States
-
Memorial Sloan Kettering Cancer CenterAgios Pharmaceuticals, Inc.RecruitingChondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3United States
-
Memorial Sloan Kettering Cancer CenterCompletedLung Cancer | Lung Cancer Metastatic | EGFR Gene MutationUnited States
-
National Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditionsUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARecruiting
-
Icahn School of Medicine at Mount SinaiMassachusetts General Hospital; National Institute of Neurological Disorders...RecruitingParkinson Disease | GBA Gene Mutation | LRRK2United States
-
Dana-Farber Cancer InstituteGenentech, Inc.RecruitingSalivary Gland Cancer | HER2 Gene MutationUnited States
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLC; Genentech, Inc.RecruitingEsophageal Cancer | Gastric Adenocarcinoma | HER2 Gene MutationUnited States
-
Rhythm Pharmaceuticals, Inc.CompletedPro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene MutationsUnited States, Israel, Canada, Germany, Greece, Italy, Portugal
-
Memorial Sloan Kettering Cancer CenterUniversity of Pennsylvania; University of California, Los Angeles; Dana-Farber... and other collaboratorsActive, not recruiting